Edition:
United States

Calithera Biosciences Inc (CALA.OQ)

CALA.OQ on NASDAQ Stock Exchange Global Select Market

4.84USD
11 Dec 2018
Change (% chg)

$0.00 (+0.00%)
Prev Close
$4.84
Open
$4.91
Day's High
$4.95
Day's Low
$4.71
Volume
30,527
Avg. Vol
68,858
52-wk High
$9.75
52-wk Low
$4.07

Latest Key Developments (Source: Significant Developments)

Calithera Biosciences Q3 Operating Loss Per Share $0.52
Wednesday, 7 Nov 2018 04:05pm EST 

Nov 7 (Reuters) - Calithera Biosciences Inc ::CALITHERA BIOSCIENCES REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS AND RECENT HIGHLIGHTS.Q3 OPERATING LOSS PER SHARE $0.52.Q3 EARNINGS PER SHARE VIEW $-0.40 -- THOMSON REUTERS I/B/E/S.AS OF SEPTEMBER 30, 2018, CASH, CASH EQUIVALENTS AND INVESTMENTS TOTALED $141.5 MILLION.EXPECT DATA ON INCB001158 TO BE PRESENTED AT A MEDICAL MEETING IN FIRST HALF OF 2019.  Full Article

Calithera Biosciences Qtrly Net Loss From Operations $11.0 Mln
Thursday, 8 Mar 2018 04:05pm EST 

March 8 (Reuters) - Calithera Biosciences Inc ::CALITHERA BIOSCIENCES REPORTS FOURTH QUARTER 2017 FINANCIAL RESULTS AND RECENT HIGHLIGHTS.CALITHERA BIOSCIENCES INC QTRLY NET LOSS FROM OPERATIONS $11.0 MILLION.CALITHERA BIOSCIENCES - EXPECTS CASH, CASH EQUIVALENTS AND INVESTMENTS WILL BE BETWEEN $105 AND $115 MILLION AT END OF 2018.CALITHERA - EXPECTS CASH, CASH EQUIVALENTS & INVESTMENTS WILL BE SUFFICIENT TO MEET CURRENT OPERATING PLAN THROUGH 2020, EXCLUSIVE OF SOME ITEMS.  Full Article

Calithera Biosciences expands clinical collaboration with Bristol-Myers Squibb
Tuesday, 7 Nov 2017 08:01am EST 

Nov 7 (Reuters) - Calithera Biosciences Inc :Initial results from Phase 2 study of CB-839 in combination with opdivo® (nivolumab) to be presented at the Society for Immunotherapy of Cancer Meeting.Calithera Biosciences Inc - ‍expanding Bristol-Myers Squibb clinical collaboration​.Calithera Biosciences Inc - ‍expanded its existing clinical collaboration with Bristol-Myers Squibb, evaluating CB-839 in combination with opdivo​.Calithera Biosciences Inc - ‍analysis of all safety evaluable patients demonstrated CB-839 was well tolerated when combined with opdivo​.Calithera Biosciences - ‍among 16 evaluable melanoma patients, one patient achieved a complete response and two patients achieved partial responses​.Calithera Biosciences Inc - ‍study will be expanded to enroll additional melanoma patients​.Calithera Biosciences Inc - ‍as part of expanded collaboration, melanoma development costs will be shared​.  Full Article

Calithera Biosciences Q3 operating loss per share $0.17
Thursday, 2 Nov 2017 07:30am EDT 

Nov 2 (Reuters) - Calithera Biosciences Inc :Calithera biosciences reports third quarter 2017 financial results and recent highlights.Q3 operating loss per share $0.17.Q3 revenue $7.3 million.Q3 earnings per share view $-0.22 -- Thomson Reuters I/B/E/S.Q3 revenue view $4.5 million -- Thomson Reuters I/B/E/S.Calithera biosciences inc - ‍as of september 30, 2017, cash, cash equivalents and investments totaled $196.5 million​.Calithera biosciences inc - qtrly ‍research and development expenses were $10.8 million compared with $6.3 million for same period in prior year​.  Full Article

Calithera Biosciences enters into sales agreement with Cowen and Co ‍​
Friday, 18 Aug 2017 04:27pm EDT 

Aug 18 (Reuters) - Calithera Biosciences Inc -:Calithera Biosciences - entered into sales agreement with Cowen And Company, Llc, or Cowen, relating to shares of co's common stock ‍​.Calithera Biosciences says co may offer and sell shares of stock having aggregate offering price of up to $50 million ‍​.  Full Article

Calithera Biosciences files for common stock offering of up to $250 mln
Tuesday, 8 Aug 2017 05:06pm EDT 

Aug 8 (Reuters) - Calithera Biosciences Inc ::Calithera Biosciences Inc files for common stock offering of up to $250 million - SEC filing‍​.  Full Article

Calithera Biosciences reports Q2 operating loss per share $0.15
Tuesday, 8 Aug 2017 04:06pm EDT 

Aug 9 (Reuters) - Calithera Biosciences Inc -:Calithera Biosciences reports second quarter 2017 financial results and recent highlights.Q2 operating loss per share $0.15.Q2 earnings per share view $-0.13 -- Thomson Reuters I/B/E/S.Q2 revenue $7.3 million.  Full Article

Calithera Biosciences initiates randomized phase 2 combination trial of CB-839 in patients with renal cell carcinoma
Monday, 7 Aug 2017 07:00am EDT 

Aug 7 (Reuters) - Calithera Biosciences Inc :Calithera Biosciences initiates a randomized phase 2 combination trial of CB-839 in patients with renal cell carcinoma.Calithera Biosciences Inc - FDA has granted fast track designation to CB-839.  Full Article

Calithera says FDA fast track designation granted to CB-839
Wednesday, 7 Jun 2017 06:45am EDT 

June 7 (Reuters) - Calithera Biosciences Inc ::Calithera Biosciences announces FDA fast track designation granted to CB-839 for treatment of patients with renal cell carcinoma.Calithera Biosciences - "look forward to initiating a global randomized trial of CB-839 in combination with everolimus for treatment of renal cell carcinoma in second half of 2017".  Full Article

Calithera announces clinical data from product candidate CB-1158
Monday, 5 Jun 2017 06:45am EDT 

June 5 (Reuters) - Calithera Biosciences Inc ::Calithera Biosciences Inc - clinical data from its product candidate CB-1158, a first-in-class arginase inhibitor​.Calithera Biosciences Inc - ‍CB-1158 was generally well tolerated with no drug-related serious adverse events​.Calithera Biosciences Inc - ‍no grade 3 treatment related adverse events were reported.​.  Full Article